AbbVie Announces Positive Topline Results from Phase 3 for Tavapadon in Parkinson's
Details : CVL-751 (tavapadon) is the first and only D1/D5 receptor partial agonist, which is being studied as a once-daily treatment for patients with parkinson’s disease.
Brand Name : CVL-751
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2024
Lead Product(s) : Tavapadon
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : AbbVie Inc
Deal Size : $8,700.0 million
Deal Type : Acquisition
AbbVie Completes Acquisition of Cerevel Therapeutics
Details : Through the acquisition, Abbvie will leverage the Cerevel pipeline, which includes CVL-75 (tavapadon), a late-stage product, D1/D5 selective partial agonist for the treatment of Parkinson's disease.
Brand Name : CVL-751
Molecule Type : Small molecule
Upfront Cash : $8,700.0 million
August 01, 2024
Lead Product(s) : Tavapadon
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : AbbVie Inc
Deal Size : $8,700.0 million
Deal Type : Acquisition
Cerevel Reports Positive Results for Tavapadon in Phase 3 Trial for Parkinson's
Details : CVL-751 (tavapadon) is the first and only D1/D5 receptor partial agonist, which is being studied as a once-daily treatment for patients with parkinson’s disease.
Brand Name : CVL-751
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 18, 2024
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
Details : Cerevel will present data demonstrating consistent clinical pharmacology across a wide range of doses of tavapadon in several Phase 1 clinical trials, supporting its potential as a promising next-generation treatment for Parkinson’s disease.
Brand Name : CVL-751
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2022
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock
Details : Cerevel Therapeutics' lead drug Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes with the goal of balancing meaningful motor activity with a favorable tolera...
Brand Name : CVL-751
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 01, 2021
Details : The Non-Dilutive Financing will fund the full Phase 3 development program for tavapadon in Parkinson’s disease, also known as the TEMPO trials.
Brand Name : CVL-751
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 13, 2021
Details : Tavapadon is an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes. The Phase 3 program will evaluate the efficacy, safety and tolerability of fixed doses (TEMPO-1) and flexible doses (TEMPO-2) of ta...
Brand Name : PF-06649751
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2020
Details : Studies to enroll approximately 1,200 patients to determine effectiveness of tavapadon across the full spectrum of early- and late-stage parkinson’s.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 14, 2020
LOOKING FOR A SUPPLIER?
Reset All
